Cardialen raises $17M for a gentler, low-energy defibrillator

Medicine Money
Cardialen’s technology delivers a sequence of smaller electrical pulses designed to slow rapid heart rates and restore a normal rhythm. (Getty/utah778)

Cardialen raised $17 million to fund its work on a low-energy defibrillator that aims to more gently restore a normal heart rhythm, with the goal of developing an implantable device that avoids the negative effects of high-energy shocks.

The series B round was led by RiverVest Venture Partners, alongside Qiming Venture Partners, HBM Healthcare Investments and Cultivation Capital.

The financing will advance the Minneapolis-based Cardialen’s clinical program with additional human safety testing of its unpinning termination therapy, which delivers a sequence of smaller electrical pulses designed to slow rapid heart rates.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Today’s implantable defibrillator therapy generates painful high-energy shocks that are associated with undesirable mortality that is expected to be reduced for patients receiving fewer shocks or a low-energy therapy,” said Cardialen’s founder and scientific advisor Igor Efimov, the Alisann & Terry Collins professor and chairman of the Department of Biomedical Engineering at The George Washington University.

In a statement, the company said its early feasibility testing suggests that its therapy may successfully treat heart rhythm disorders with substantially less energy compared to existing defibrillators.

“We think Cardialen’s UPT therapy meets a unique need in the large current and potential defibrillator market,” said Jay Schmelter, managing director of RiverVest Ventures, who joins the company’s board of directors. “Early UPT therapy results look promising and we’re looking forward to partnering with Cardialen on this innovative approach.”

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.